Evaluation of bone metabolism after the use of an inhaled glucocorticoid (flunisolide) in patients with moderate asthma

Evaluation of bone metabolism after the use of an inhaled glucocorticoid (flunisolide) in patients with moderate asthma

Autor Hauache, O. M. Google Scholar
Amarante, ECJ Google Scholar
Vieira, JGH Google Scholar
Faresin, S. M. Google Scholar
Fernandes, ALG Google Scholar
Jardim, JR Google Scholar
Lazaretti-Castro, M. Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo CONCLUSIONS the use of inhaled flunisolide 1000 mu g/day for 10weeks had no suppressive effect on adrenal function in the majority of asthmatic patients studied, However, the effects seen on bone and mineral metabolism, evidenced by the significant fall in osteocalcin and pyridinoline levels, may indicate a possible systemic effect of this drug. Clinical consequences of long-term treatment with flunisolide need to be further evaluated,OBJECTIVE We have investigated the effects of the inhaled corticosteroid flunisolide on bone metabolism and adrenal function in patients with moderate asthma,SUBJECTS and DESIGN Twenty ambulatory patients (13 females, 7 males, mean age +/- SD of 36.4 +/- 12.4 years) with moderate asthma were recruited, None had taken corticosteroids for at least 1 month. Flunisolide 500 mu g was given twice a day for 10weeks, without any other medication. Blood and urine were collected before and at the end of treatment course. Cortisol (basal and Ih after ACTH 250 mu g i,v,) was measured to evaluate adrenal function. A peak cortisol response of 496 nmol/l was considered an adequate response. Serum ionized calcium, intact PTH, plasma osteocalcin (OC) and urinary pyridinoline (Pyr) and deoxy-pyridinoline (D-Pyr) were measured to evaluate bone metabolism, Wilcoxon paired test was performed for statistical analysis. Results are expressed as mean i SD.RESULTS in most patients (85%), there was no difference after treatment with flunisolide on basal and stimulated cortisol levels. We found a significant decrease of CC (3.55 i 1.42 to 2.97 +/- 1.05 nmol/l) and Pyr (66.4 +/- 20.0 to 59.5 +/- 24.9 pmol/mu mol creatinine) levels after treatment (P<0.05). We also observed a positive correlation between the variations seen in pre and post treatment values of CC and Pyr/D-Pyr.
Idioma Inglês
Data de publicação 1999-07-01
Publicado em Clinical Endocrinology. Oxford: Blackwell Science Ltd, v. 51, n. 1, p. 35-39, 1999.
ISSN 0300-0664 (Sherpa/Romeo, fator de impacto)
Publicador Blackwell Science Ltd
Extensão 35-39
Fonte http://dx.doi.org/10.1046/j.1365-2265.1999.00658.x
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000081623400006
Endereço permanente http://repositorio.unifesp.br/handle/11600/26108

Exibir registro completo


Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções



Minha conta